PERTH, Australia – Mesoblast Ltd. has signed a deal with China's Tasly Pharmaceutical Group that opens up the massive greater China market to the Aussie stem cell company to develop, manufacture and commercialize two of its late-stage allogeneic mesenchymal precursor cell (MPC) candidates for cardiovascular indications.